荣昌生物:PSMA/B7H3 ADC申报IND正心Ecosphere

动脉网
Mar 08

2026年3月2日,荣昌生物RC288注射液上市申请获NMPA受理。RC288是荣昌生物自主研发的PSMA/B7H3 ADC,采用TOP1i为payload,通过可裂解linker偶联到抗体,运用定点偶联技术,DAR值为8,临床前期研究显示其抗肿瘤活性优异且安全性良好。在开发纬迪西妥单抗后,荣昌生物建立TOPi ADC技术平台,重点推进CDCP1 ADC、PSMA/B7H3 ADC,前者重点探索结...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10